Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phibro Animal Health (PAHC)

Phibro Animal Health names Dani Bendheim CEO and President effective July 1, 2026

Neutral Impact 4 of 5 leadership Written later

Phibro Animal Health said Daniel (Dani) Bendheim will become Chief Executive Officer and President effective July 1, 2026, under a new employment agreement with a $850,000 base salary. He also received a grant of 300,000 performance-based restricted stock units that vest only if the company's 90-day average stock price reaches $70 to $100 by June 30, 2031.

Key points

  • Bendheim's base salary is $850,000 annually, with a target bonus of 50% of base salary.
  • The 300,000 RSUs vest in 25% increments tied to a 90-day average stock price from $70 to $100 or above, with no vesting below $70.
  • Severance includes six months of base salary on death or disability and up to 18 months of company-subsidized COBRA coverage on termination without Cause or resignation.

The filing

CompanyPhibro Animal Health (PAHC)
Form8-K, current report
Filed with the SECJun 26, 2026, 5:07 PM ET
Accession number0001104659-26-078323

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.